A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
作者全名："Zhou, C.; Li, W.; Song, Z.; Zhang, Y.; Zhang, Y.; Huang, D.; Yang, Z.; Zhou, M.; Mao, R.; Huang, C.; Li, X.; Wang, J."
作者地址："[Zhou, C.; Li, W.] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Sch Med, Shanghai, Peoples R China; [Song, Z.; Zhang, Y.] Zhejiang Canc Hosp, Phase Clin Trial Ward 1, Hangzhou, Peoples R China; [Zhang, Y.] Zhejiang Canc Hosp, Phase Clin Trial Ward 1, Hangzhou, Zhejiang, Peoples R China; [Zhang, Y.] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China; [Huang, D.] Tianjin Med Univ Canc Inst & Hosp, Internal Med Dept Lung Tumor, Tianjin, Peoples R China; [Yang, Z.] Chongqing Med Univ, Dept Canc Ctr, Affiliated Hosp 2, Chongqing, Peoples R China; [Zhou, M.] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pulm & Crit Care Med, Sch Med, Shanghai, Peoples R China; [Mao, R.; Huang, C.; Li, X.; Wang, J.] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res Dev, Shanghai, Peoples R China"
通信作者：
来源：ANNALS OF ONCOLOGY
ESI学科分类：CLINICAL MEDICINE
WOS号：WOS:001087480203512
JCR分区：Q1
影响因子：50.5
年份：2023
卷号：34
期号：
开始页：S1273
结束页：S1273
文献类型：Meeting Abstract
关键词：
摘要：
基金机构：Jiangsu Hengrui Pharmaceuticals
基金资助正文：Jiangsu Hengrui Pharmaceuticals.
